As Chairman and CEO, Candace Kendle, PharmD, has provided the overall vision and strategy to grow Kendle into a leading, global CRO. Under her leadership, Kendle has become the fourth-largest provider of Phase II-IV development services worldwide with more than 3,000 associates and operations across North America, Europe, Asia/Pacific, Latin America and Africa.
In the thriving and increasingly competitive e-clinical trials marketplace, Dr. Kendle's focus has been on positioning the company to compete at the highest level for large global clinical development programs. In support of this goal, she led Kendle through a strategic transformation in 2006 with the acquisition of the Phase II-IV Clinical Services business of Charles River Laboratories, increasing the company's size by 50 percent and strengthening its position in the CRO industry.
Dr. Kendle is a founding member and Immediate Past Chair (2006) of the Association of Clinical Research Organizations (ACRO), which fosters continued advancement of medical product development and expedites the introduction of new medicines and new treatments to improve health and save lives.
Dr. Kendle is a member of the Harvard Business School Alumni Association Board and a member of the Committee of 200, an organization of preeminent women entrepreneurs and corporate leaders. Dr. Kendle also serves as a director of the H.J. Heinz Company.
Prior to founding the company, Dr. Kendle held senior faculty positions in the pharmaceutical programs of several leading institutions. More recently, she played a key role in the development of the master of science program in global drug development at the University of Cincinnati.